Noteworthy

Sep 01, 2010
Pharmaceutical Executive
Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP
Sep 01, 2010
Pharmaceutical Executive
A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
Jul 01, 2010
Pharmaceutical Executive
Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?
Jul 01, 2010
Pharmaceutical Executive
Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.
Jul 01, 2010
Pharmaceutical Executive
FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.
Jun 25, 2010
Pharmaceutical Executive
Strong, skilled management is on the agenda as never before. Find out who made 2010's roster of high-potential change masters—and how they plan to lead the industry through the turbulent times ahead.
Jun 17, 2010
Pharmaceutical Executive
A new "upstream" healthcare model may help deliver on the longstanding promise of personalized medicine.
May 11, 2010
Pharmaceutical Executive
Pfizer's Specialty Product Business Unit leader discusses his vision for the drug giant's specialty business; now the largest in the industry.
Apr 27, 2010
Pharmaceutical Executive
As head of GSK's North American pharma, Deirdre Connelly has the daunting challenge of trying to turn around the sluggish US market. If she succeeds, Connelly may find herself auditioning as the first female Big Pharma CEO.
Apr 13, 2010
Pharmaceutical Executive
The faces and names behind the year's best pharmaceutical advertising.
native1_300x100
lorem ipsum